MOODY’S-ANALYTICS
9.11.2020 10:02:09 CET | Business Wire | Press release
Moody’s Analytics announced today a new partnership with The Business School (formerly Cass) at City, University of London, to build a database of loan-level commercial real estate (CRE) information covering the UK and Europe. The initiative will extend the Business School’s UK CRE lending survey under the Moody’s Analytics Data Alliance framework.
The COVID-19 pandemic has disrupted CRE fundamentals and highlighted the need for greater clarity around market drivers across sectors and between geographies. By participating in this initiative, lenders and other market participants will benefit from access to aggregate industry data, for enhanced market clarity, as well as robust analytics for benchmarking.
“The City-Moody’s Analytics initiative offers the exciting prospect of granular data pooling across the commercial real estate finance market. This will improve market transparency and allow for more robust data-driven analysis, thus strengthening informed credit flows,” said Peter Cosmetatos, CEO of the Commercial Real Estate Finance Council Europe. “Industry leaders and the Bank of England have previously recognized the importance of loan-level data pooling—this market-led initiative could be an important step towards achieving it.”
The data will be aggregated as part of the Moody’s Analytics Data Alliance, a collaborative effort of leading financial institutions and Moody's Analytics to create the world's largest collection of credit risk data. It is one of the world’s largest and most comprehensive data consortia with participation from more than 120 of the world’s leading banks, insurers, asset managers, and multi-lateral development banks. This initiative expands the Moody’s Analytics US CRE data consortium, which comprises data on loans worth $588B+, in 105,000+ properties covering 361 metropolitan areas, to the UK and Europe.
“We are delighted to partner with The Business School at City, University of London to create this essential CRE resource in the UK and Europe, which aligns with our commitment to helping the CRE industry address fundamental shifts caused by the pandemic,” said Jacob Grotta, Head of Risk and Finance Solutions at Moody’s Analytics. “The aim of the Data Alliance is to provide institutions with high-quality data, robust analytics, and advanced modelling capabilities for managing credit risk throughout the cycle.”
Co-leading the initiative is Dr. Nicole Lux, Senior Research Fellow at The Business School (formerly Cass), University of London. With extensive experience in real estate data collection, Dr. Lux conducts the UK CRE lending survey, which has been gathering data from more than 100 participant firms for more than 20 years to produce a comprehensive record of CRE lending in the market. Dr. Lux will work with industry participants to gather the loan-level information on behalf of the City-Moody’s Analytics initiative in the UK.
“Moody’s Analytics brings a wealth of expertise in collecting and parsing CRE and credit data in the US market,” said Dr. Lux. “I’m looking forward to working with the Data Alliance to broaden the scope of our CRE lending survey to encompass loan-level data and create more powerful analytics and benchmarking for CRE market participants in Europe.”
Learn more about the Moody’s Analytics Data Alliance.
About Moody’s Analytics
Moody’s Analytics provides financial intelligence and analytical tools to help business leaders make better, faster decisions. Our deep risk expertise, expansive information resources, and innovative application of technology help our clients confidently navigate an evolving marketplace. We are known for our industry-leading and award-winning solutions, made up of research, data, software, and professional services, assembled to deliver a seamless customer experience. We create confidence in thousands of organizations worldwide, with our commitment to excellence, open mindset approach, and focus on meeting customer needs. For more information about Moody’s Analytics, visit our website or connect with us on Twitter and LinkedIn .
Moody's Analytics is a subsidiary of Moody's Corporation (NYSE: MCO). Moody's Analytics is a subsidiary of Moody's Corporation (NYSE: MCO). Moody’s Corporation reported revenue of $4.8 billion in 2019, employs approximately 11,200 people worldwide and maintains a presence in 40 countries.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201109005455/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Yubico Appoints Poupak Modirassari Enbom as Chief Marketing Officer to Accelerate Global Momentum and Drive Market Leadership30.3.2026 15:00:00 CEST | Press release
Yubico (NASDAQ STOCKHOLM: YUBICO), the creator of the most secure passkeys and a leading provider of hardware authentication security keys, today announced the appointment of Poupak Enbom as Chief Marketing Officer (CMO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330278027/en/ Enbom joins Yubico at a pivotal moment as organizations worldwide accelerate the shift to phishing-resistant authentication and modern identity security in the age of AI. “We’re excited to welcome Poupak to Yubico,” said Jerrod Chong, acting chief executive officer, Yubico. “As the threat landscape evolves with AI-driven attacks and increasing automation, organizations are rethinking how they secure digital identities of both humans and AI agents at scale. She brings a unique combination of technical depth, global leadership, and customer-first mindset that will help us continue to expand our impact and support our customers and partners around
Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 14:00:00 CEST | Press release
Fuel manufactured at Springfields has generated enough energy to supply the UK’s electricity demand for 26 years, avoiding the emission of nearly 3 billion tonnes of CO2 The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 5
HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 14:00:00 CEST | Press release
HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom